Diagnostic Test Kits for Dengue Virus Detection Evaluated
|
By LabMedica International staff writers Posted on 28 Oct 2014 |
|
Image: An enzyme-linked immunosorbent assay (ELISA) kit for dengue virus NS1 antigen (Photo courtesy of Diagnostic Automation Inc.).
Laboratory diagnosis of dengue with a single serum specimen obtained during the acute phase of the illness requires tests to detect immunoglobulin M (IgM) antibodies to Dengue virus or the virus genome.
Commercially available diagnostic test kits for detection of the Dengue virus (DENV) non-structural protein 1 (NS1) and anti-DENV IgM have been evaluated for their sensitivity and specificity and other performance characteristics.
An international team of scientists led by those at the [US] Centers for Disease Control and Prevention (CDC; San Juan, Puerto Rico) examined newly available commercial tests that detect the virus protein NS1, as well as new tests for IgM anti-DENV in microplate or rapid diagnostic test (RDT) formats. This analytic study used specimens from laboratory confirmed dengue patients worldwide, which makes the results widely generalizable.
A DENV NS1 panel cconsisted of a total of 390 dengue patient serum specimens in three sub-panels: 192 dengue patients who were DENV positive by virus isolation and/or polymerase chain reaction (PCR) for DENV ribonucleic acid (RNA), 146 DENV RNA or culture negatives, and 52 challenge specimens from other illnesses or conditions. An anti-DENV IgM panel consisted of three subpanels with 527 patient serum specimens: 228 anti-DENV IgM positive paired specimens from patients with dengue and 155 DENV IgM negative and 144 challenge specimens. All specimens were tested by the solid-phase anti-DENV IgM Antibody Capture Enzyme Linked Immunosorbent Assay (IgM MAC-ELISA).
The DENV kits from seven different manufacturers were tested. The results were analyzed to determine sensitivity, specificity, inter-laboratory and inter-reader agreement, lot-to-lot variation and ease-of-use. NS1 ELISA sensitivity was 60% to 75% and specificity 71% to 80%; NS1 RDT sensitivity was 38% to 71% and specificity 76% to 80%; the IgM anti-DENV RDTs sensitivity was 30% to 96%, with a specificity of 86% to 92%, and IgM anti-DENV ELISA sensitivity was 96% to 98% and specificity 78% to 91%.
The authors concluded that NS1 tests were generally more sensitive in specimens from the acute phase of dengue and in primary DENV infection, whereas IgM anti-DENV tests were less sensitive in secondary DENV infections. The reproducibility of the NS1 RDTs ranged from 92% to 99% and the IgM anti-DENV RDTs from 88% to 94%.The study was published on October 16, 2014, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Centers for Disease Control and Prevention
Commercially available diagnostic test kits for detection of the Dengue virus (DENV) non-structural protein 1 (NS1) and anti-DENV IgM have been evaluated for their sensitivity and specificity and other performance characteristics.
An international team of scientists led by those at the [US] Centers for Disease Control and Prevention (CDC; San Juan, Puerto Rico) examined newly available commercial tests that detect the virus protein NS1, as well as new tests for IgM anti-DENV in microplate or rapid diagnostic test (RDT) formats. This analytic study used specimens from laboratory confirmed dengue patients worldwide, which makes the results widely generalizable.
A DENV NS1 panel cconsisted of a total of 390 dengue patient serum specimens in three sub-panels: 192 dengue patients who were DENV positive by virus isolation and/or polymerase chain reaction (PCR) for DENV ribonucleic acid (RNA), 146 DENV RNA or culture negatives, and 52 challenge specimens from other illnesses or conditions. An anti-DENV IgM panel consisted of three subpanels with 527 patient serum specimens: 228 anti-DENV IgM positive paired specimens from patients with dengue and 155 DENV IgM negative and 144 challenge specimens. All specimens were tested by the solid-phase anti-DENV IgM Antibody Capture Enzyme Linked Immunosorbent Assay (IgM MAC-ELISA).
The DENV kits from seven different manufacturers were tested. The results were analyzed to determine sensitivity, specificity, inter-laboratory and inter-reader agreement, lot-to-lot variation and ease-of-use. NS1 ELISA sensitivity was 60% to 75% and specificity 71% to 80%; NS1 RDT sensitivity was 38% to 71% and specificity 76% to 80%; the IgM anti-DENV RDTs sensitivity was 30% to 96%, with a specificity of 86% to 92%, and IgM anti-DENV ELISA sensitivity was 96% to 98% and specificity 78% to 91%.
The authors concluded that NS1 tests were generally more sensitive in specimens from the acute phase of dengue and in primary DENV infection, whereas IgM anti-DENV tests were less sensitive in secondary DENV infections. The reproducibility of the NS1 RDTs ranged from 92% to 99% and the IgM anti-DENV RDTs from 88% to 94%.The study was published on October 16, 2014, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
Centers for Disease Control and Prevention
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Latest Microbiology News
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
- Culture-Free Platform Rapidly Identifies Blood Stream Infections
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
Molecular Diagnostics
view channel
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read more
Novel Point-of-Care Technology Delivers Accurate HIV Results in Minutes
HIV diagnostic methods have traditionally relied on detecting HIV-specific antibodies, which typically appear weeks after infection. This delayed detection has hindered early diagnosis, complicating patient... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Pathology
view channel
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
